Targets › ACE2
4 programs from 3 companies in 4 trials: 2 Phase 3, 2 Phase 1; Oncology, Neurology, Cardiovascular; next expected readout Dec 2026.
Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis. Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and…. (UniProt, Q9BYF1)
Open in Phaseline: the race on ACE2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Monash University | Elasomeran Spike glycoprotein vaccine antigen | ACE2 | Phase 3 | HIV | Dec 2026 |
| Monash University | Pfizer Bivalent COVID-19 Vaccine mRNA vaccine encoding SARS-CoV-2 spike protein (original strain and Omicron BA.1) | ACE2 | Phase 3 | HIV | Dec 2026 |
| University of Arizona | Angiotensin (1-7) Angiotensin (1-7) receptor agonist; acts through the Mas receptor to promote neuroprotecti | ACE2 | Phase 1 | Traumatic Brain Injury | Sep 2027 |
| Vanderbilt University | Angiotensin-(1-7) Angiotensin-(1-7) receptor agonist; endogenous peptide that promotes vasodilation and may | ACE2 | Phase 1 | Obesity | Dec 2029 |
HIV (2) Traumatic Brain Injury (1) Obesity (1)
other (2), small molecule (2)
Monash University (2) University of Arizona (1) Vanderbilt University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.